ESR2 and ovarian carcinoma: Indeed, in ovarian cancer BG1 cells expressing both ERs, we previously observed that ERα-selective agonists activated cell proliferation more efficiently than did ERβ-selective ligands or ER pan-agonists (Docquier et al. 2013).